Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 79 for “"NF2"”.

  1. Targeting Aldehyde Dehydrogenases in NF2-null Meningioma and Schwannoma

    … driven by loss or mutation of the gene NF2, which encodes the tumour suppressor protein Merlin. Dysregulated Hippo pathway signalling, caused by NF2 loss, drives overexpression of aldehyde dehydrogenase 1A1 (ALDH1A1) in NF2-null schwannoma. High expression of ALDH1A1, and the related …

    plymouth Repository record for Targeting Aldehyde Dehydrogenases in NF2-null Meningioma and Schwannoma (opens in a new tab)

  2. The past, present, and future directions of treatment for NF2- related vestibular schwannomas

    NF2-related schwannomatosis (NF2-SWN), an autosomal dominant disorder is characterized by tumorigenesis in both the central and peripheral nervous systems. The “hallmark” characterization of NF2-SWN is the presence of bilateral vestibular schwannomas, however other tumors can include meningiomas, …

    bu Repository record for The past, present, and future directions of treatment for NF2- related vestibular schwannomas (opens in a new tab)

  3. The role of the tumor suppressor gene, NF2, in the development of malignant mesothelioma

    … therapeutic options. Neurofibromatosis Type 2 (NF2) is one of the most commonly inactivated tumor suppressor genes in mesothelioma. The downstream signaling pathways that may be disrupted as a result of this inactivation are not entirely understood. Conversely, the tumor suppressor gene that is …

    montana Repository record for The role of the tumor suppressor gene, NF2, in the development of malignant mesothelioma (opens in a new tab)

  4. The role of the tumor suppressor gene, NF2, in the development of malignant mesothelioma

    … therapeutic options. Neurofibromatosis Type 2 (NF2) is one of the most commonly inactivated tumor suppressor genes in mesothelioma. The downstream signaling pathways that may be disrupted as a result of this inactivation are not entirely understood. Conversely, the tumor suppressor gene that is …

    montana-tech Repository record for The role of the tumor suppressor gene, NF2, in the development of malignant mesothelioma (opens in a new tab)

  5. Mechanisms Promoting Phosphorylation Of The Nf2 Tumor Suppressor And Its Effects On Schwann Cell Development

    … and other peripheral neuropathies. The nf2 gene encodes the protein Schwannomin, or merlin. Schwannomin (Sch) is a membrane-cytoskeletal linking protein that suppresses cell proliferation at high cell density and modulates cell shape. Sch's tumor suppressive activity is regulated by its …

    ucf Repository record for Mechanisms Promoting Phosphorylation Of The Nf2 Tumor Suppressor And Its Effects On Schwann Cell Development (opens in a new tab)

  6. Radiological and clinical response of Neurofibromatosis type 2 (NF2) associated tumours in patients receiving bevacizumab

    Neurofibromatosis type 2 (NF2) patients develop multiple nervous system tumours including bilateral vestibular schwannomas (VS). The tumours and their treatment are associated with deafness, neurological disability and mortality. The UK nationally-commissioned specialty NF2 service introduced …

    unsw Repository record for Radiological and clinical response of Neurofibromatosis type 2 (NF2) associated tumours in patients receiving bevacizumab (opens in a new tab)

  7. NEUROFIBROMATOSIS TYPE 2 PROTEIN (NF2) AS A REGULATOR OF TUMOR SUPPRESSORS AND VIRAL ONCOPROTEINS IN HUMAN GLIOBLASTOMA

    … their specific tumor suppressor genes, NF1 and NF2, respectively. Inactivation of the NF2 gene, results in the development of several multiple benign nervous system tumors. Traditionally, NF2 is viewed as a scaffolding protein primarily located at the plasma membrane, where it prevents excessive …

    temple Repository record for NEUROFIBROMATOSIS TYPE 2 PROTEIN (NF2) AS A REGULATOR OF TUMOR SUPPRESSORS AND VIRAL ONCOPROTEINS IN HUMAN GLIOBLASTOMA (opens in a new tab)

  8. Preliminary Study on How Tumor Suppressor Nf2 Inhibits Transcriptional Coactivators Yap/Taz in the Developing Mouse Brain

    … the tumor suppressor neurofibromatosis 2 (Nf2) was shown to regulate the balance of neural progenitor proliferation and differentiation in the developing mouse brain through the Hippo pathway effectors, transcriptional coactivators Yap/Taz. The molecular mechanism of how Nf2 regulates …

    tenn-hsc Repository record for Preliminary Study on How Tumor Suppressor Nf2 Inhibits Transcriptional Coactivators Yap/Taz in the Developing Mouse Brain (opens in a new tab)

  9. Investigating the Role of the Hippo Pathway Member Nf2 in the Segregation of Trophectoderm and Inner Cell Mass

    … the role of the upstream Hippo pathway member Nf2 in TE/ICM segregation. First, using a dominant negative approach, I show that Nf2 is required in a cell-autonomous manner for the proper localization of Yap in inside cells of the embryo. Second, by generating both zygotic and maternal/zygotic …

    toronto-retro Repository record for Investigating the Role of the Hippo Pathway Member Nf2 in the Segregation of Trophectoderm and Inner Cell Mass (opens in a new tab)

  10. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours

    … causes life-altering symptoms. Individuals with NF2-related schwannomatosis may develop schwannomas and meningiomas, increasing tumour burden. The primary treatment for large or symptomatic schwannomas and meningiomas is surgical resection, which may not be suitable in cases involving tumours …

    plymouth Repository record for Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours (opens in a new tab)

  11. Exploring the Potential use of TEAD Inhibition as Part of a Combination Therapy for NF2-Deficient Schwannoma and Meningioma.

    NF2-related Schwannomatosis is a genetic cancer predisposition syndrome, resulting in the development of schwannoma, meningioma and ependymoma tumours. Although surgical resection and adjuvant radiotherapy can be used, new avenues of therapeutic development are essential to target inoperable and …

    plymouth Repository record for Exploring the Potential use of TEAD Inhibition as Part of a Combination Therapy for NF2-Deficient Schwannoma and Meningioma. (opens in a new tab)

  12. Targeted Therapy Development for Neurofibromatosis Type 2

    Neurofibromatosis type 2 (NF2) is a debilitating disease characterized by the formation of bilateral vestibular schwannomas, which compress the vestibulocochlear nerve and cause deafness. Additional peripheral schwannomas, meningiomas and ependymomas may also form. NF2 is caused by mutations in the …

    ucf Repository record for Targeted Therapy Development for Neurofibromatosis Type 2 (opens in a new tab)

  13. Merlin Regulation of Mouse Spinal Cord Neural Precursor Cell Function

    … tumors is surgery. Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited cancer predisposition syndrome, caused by a germline mutation in the NF2 tumor suppressor gene, in which affected individuals develop spinal cord (SC) ependymomas. In this dissertation, we use NF2 as a …

    wustl Repository record for Merlin Regulation of Mouse Spinal Cord Neural Precursor Cell Function (opens in a new tab)

  14. Integrative analysis of differentially regulated proteins in meningioma

    … 50% of meningiomas harbour mutations in the NF2 gene that resides on chromosome 22 and codes for a protein named “Merlin”. Moreover, frequent mutations can be observed in genes including AKT1, KLF4, TRAF7, SMO, and PIK3CA. Based on mutations, meningiomas can be divided into different genomic …

    plymouth Repository record for Integrative analysis of differentially regulated proteins in meningioma (opens in a new tab)

  15. Analyse des Neurofibromatose 2 Gens in seltenen Meningeomvarianten

    … Mutationen des Tumorsuppressorgens NF2 werden in 30% bis 60% sporadisch auftretender Meningeome beschrieben. Die große Mehrheit der Meningeome, die in bisherige Studien eingeschlossen wurden, gehört zu den häufig vorkommenden Subtypen. Unter diesen Subtypen des WHO-Grades I fallen …

    fu-berlin Repository record for Analyse des Neurofibromatose 2 Gens in seltenen Meningeomvarianten (opens in a new tab)

  16. Target Validation For Neurofibromatosis Type 2 Therapeutics.

    Neurofibromatosis type 2 (NF2) is a benign tumor disease of the nervous system. Development of bilateral vestibular schwannomas is characteristic of NF2; however patients frequently present schwannomas on other nerves, as well as meningiomas and ependymomas. Currently, there are no drug therapies …

    ucf Repository record for Target Validation For Neurofibromatosis Type 2 Therapeutics. (opens in a new tab)

  17. Outcomes of Auditory Brainstem Implantation in Adults with Postlingual Deafness: A Systematic Review

    … and to compare outcomes of ABIs in adults with NF2/tumors to adults without NF2. Methods: A comprehensive search utilizing various peer reviewed databases via the City University of New York (CUNY) Graduate Center Library was conducted to identify relevant studies investigating …

    cuny-grad Repository record for Outcomes of Auditory Brainstem Implantation in Adults with Postlingual Deafness: A Systematic Review (opens in a new tab)

  18. Role of driver mutations in mesothelioma using proteogenomics

    … alterations in PM have identified BAP1 and NF2 as tumour suppressor genes with loss of function mutations in a large proportion of PM patients. Currently, there is a lack of understanding on the deeper molecular effects of the loss of function of NF2 and BAP1, highlighting the need to …

    edinburgh Repository record for Role of driver mutations in mesothelioma using proteogenomics (opens in a new tab) Restricted access

  19. Neurofibromatosis type 2: Results of an Italian multi-center study on the clinical features of the disease in childhood and on response to treatment with bevacizumab

    Introduzione: La neurofibromatosi 2 (NF2) è una malattia monogenica autosomica dominante causata da mutazioni nel gene onco-soppressore NF2, con conseguente mancata produzione della Merlina (o Schwannomina), che agisce come onco-soppressore. Gli individui affetti sono predisposti a sviluppare …

    catania Repository record for Neurofibromatosis type 2: Results of an Italian multi-center study on the clinical features of the disease in childhood and on response to treatment with bevacizumab (opens in a new tab)

  20. The added value of BAP1 immunohistochemistry and fluorescence in situ hybridisation for CDKN2A/p16 and NF2 in the diagnosis and prognostication of pleural mesothelioma

    Background: Mesothelioma is a rare but aggressive malignancy with therapeutic options that are generally palliative. The malignancy can be challenging to diagnose, commonly due to scant samples, often requiring patients to undergo multiple procedures before a definitive diagnosis can be reached. In …

    edithcowan Repository record for The added value of BAP1 immunohistochemistry and fluorescence in situ hybridisation for CDKN2A/p16 and NF2 in the diagnosis and prognostication of pleural mesothelioma (opens in a new tab)

Page 1 of 4